Cargando…
From SARS to COVID-19: What lessons have we learned?
After the outbreak of severe acute respiratory syndrome (SARS) in November 2002, coronaviruses (CoVs) received worldwide attention. On December 1, 2019, the first case of coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), was reported in Wuhan, China, and CoVs returned...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442131/ https://www.ncbi.nlm.nih.gov/pubmed/32888871 http://dx.doi.org/10.1016/j.jiph.2020.08.001 |
_version_ | 1783573417655533568 |
---|---|
author | Liu, Qin Xu, Kaiyuan Wang, Xiang Wang, Wenmei |
author_facet | Liu, Qin Xu, Kaiyuan Wang, Xiang Wang, Wenmei |
author_sort | Liu, Qin |
collection | PubMed |
description | After the outbreak of severe acute respiratory syndrome (SARS) in November 2002, coronaviruses (CoVs) received worldwide attention. On December 1, 2019, the first case of coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), was reported in Wuhan, China, and CoVs returned to public view. On January 30, 2020, the World Health Organization (WHO) declared that the COVID-19 epidemic is a public health emergency of international concern (PHEIC), and on March 11, 2020, the WHO classified COVID-19 as a pandemic disease. As of July 31, 2020, COVID-19 has affected 216 countries and regions, with 17,064,064 confirmed cases and 668,073 deaths, and the number of new cases has been increasing daily. Additionally, on March 19, 2020, there were no new confirmed cases in China, providing hope and valuable experience for the international community. In this review, we systematically compare COVID-19 and SARS in terms of epidemiology, pathogenesis and clinical characteristics and discuss the current treatment approaches, scientific advancements and Chinese experience in fighting the epidemic to combat the novel coronavirus pandemic. We also discuss the lessons that we have learned from COVID-19 and SARS. |
format | Online Article Text |
id | pubmed-7442131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74421312020-08-24 From SARS to COVID-19: What lessons have we learned? Liu, Qin Xu, Kaiyuan Wang, Xiang Wang, Wenmei J Infect Public Health Review Article After the outbreak of severe acute respiratory syndrome (SARS) in November 2002, coronaviruses (CoVs) received worldwide attention. On December 1, 2019, the first case of coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), was reported in Wuhan, China, and CoVs returned to public view. On January 30, 2020, the World Health Organization (WHO) declared that the COVID-19 epidemic is a public health emergency of international concern (PHEIC), and on March 11, 2020, the WHO classified COVID-19 as a pandemic disease. As of July 31, 2020, COVID-19 has affected 216 countries and regions, with 17,064,064 confirmed cases and 668,073 deaths, and the number of new cases has been increasing daily. Additionally, on March 19, 2020, there were no new confirmed cases in China, providing hope and valuable experience for the international community. In this review, we systematically compare COVID-19 and SARS in terms of epidemiology, pathogenesis and clinical characteristics and discuss the current treatment approaches, scientific advancements and Chinese experience in fighting the epidemic to combat the novel coronavirus pandemic. We also discuss the lessons that we have learned from COVID-19 and SARS. The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2020-11 2020-08-21 /pmc/articles/PMC7442131/ /pubmed/32888871 http://dx.doi.org/10.1016/j.jiph.2020.08.001 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Liu, Qin Xu, Kaiyuan Wang, Xiang Wang, Wenmei From SARS to COVID-19: What lessons have we learned? |
title | From SARS to COVID-19: What lessons have we learned? |
title_full | From SARS to COVID-19: What lessons have we learned? |
title_fullStr | From SARS to COVID-19: What lessons have we learned? |
title_full_unstemmed | From SARS to COVID-19: What lessons have we learned? |
title_short | From SARS to COVID-19: What lessons have we learned? |
title_sort | from sars to covid-19: what lessons have we learned? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442131/ https://www.ncbi.nlm.nih.gov/pubmed/32888871 http://dx.doi.org/10.1016/j.jiph.2020.08.001 |
work_keys_str_mv | AT liuqin fromsarstocovid19whatlessonshavewelearned AT xukaiyuan fromsarstocovid19whatlessonshavewelearned AT wangxiang fromsarstocovid19whatlessonshavewelearned AT wangwenmei fromsarstocovid19whatlessonshavewelearned |